• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Off-label drug use in oncology: a systematic review of literature

    Thumbnail
    Author(s)
    Saiyed, MM
    Ong, PS
    Chew, L
    Griffith University Author(s)
    Saiyed, Masnoon
    Year published
    2017
    Metadata
    Show full item record
    Abstract
    What is known and objective: The off‐label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off‐label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decision‐making, increased out‐of‐pocket costs for patients and ethical concerns around the lack of informed consent. Currently, data pertaining to the global prevalence of off‐label use in cancer therapy are lacking. The aim of this review was to ...
    View more >
    What is known and objective: The off‐label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off‐label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decision‐making, increased out‐of‐pocket costs for patients and ethical concerns around the lack of informed consent. Currently, data pertaining to the global prevalence of off‐label use in cancer therapy are lacking. The aim of this review was to provide an overview of off‐label drug use prevalence in oncology. Methods: A systematic literature search was performed in PubMed as per the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines from 1975 to 2016. Studies assessing the prevalence of off‐label use of anticancer drugs were included. Data synthesis: Of the 199 eligible papers retrieved, 23 studies were included in this systematic literature review. Off‐label drug use in inpatients ranged from 18% to 41%. Among adult patients with cancer, 13%–71% received a minimum of one off‐label chemotherapy. The main reasons for off‐label drug use were ‘drug unapproved for specific tumour’ and ‘modified drug applications’. Among adults, metastatic cancers and palliative care patients received the most off‐label drugs. The off‐label drug use unsupported by standard treatment guidelines or drug compendia was in the range of 7%–31%. Conclusion: Off‐label drug use in cancer therapy is commonly practised but outcomes could vary significantly. Hence, greater scrutiny and robust clinical guidance is needed to establish the favourable benefit–risk ratio for patients at the time of prescribing at each level of oncology care to facilitate rational off‐label prescribing.
    View less >
    Journal Title
    Journal of Clinical Pharmacy and Therapeutics
    Volume
    42
    Issue
    3
    DOI
    https://doi.org/10.1111/jcpt.12507
    Subject
    Pharmacology and pharmaceutical sciences
    Science & Technology
    Life Sciences & Biomedicine
    Pharmacology & Pharmacy
    cancer pharmacotherapy
    off-label
    Publication URI
    http://hdl.handle.net/10072/387993
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander